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Introduction
Serum autoantibodies (autoAbs) represent the hallmark of 
systemic autoimmune rheumatic diseases (SARD) (1), and 
can be detected years before the development of clinical 
manifestations and diagnosis (2). Currently, a high number 
of autoAbs are routinely detected worldwide to assist the 
clinicians in the diagnosis of SARD and their importance is 
related to the fact that they correlate with disease phenotype 
and severity, independently from their frequency. However, 
some patients are still defined “seronegative” when no 
known or specific autoAb is detected (3). 
Patients affected by SARD can develop various disease 
manifestations, which share in most cases serum ANA 
positivity, and they may be diagnosed as systemic sclerosis 
(SSc), systemic lupus erythematosus (SLE), Sjögren’s 
syndrome (SjS), polymyositis and dermatomyositis (PM/
DM) and mixed connective tissue disease (MCTD). The 
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clinical manifestations of SARD may also overlap in some 
cases (4), and the identification of serum autoAbs is of major 
importance not only for SARD diagnosis but also for their 
prognosis, as they may predict internal organ involvement 
and/or cancer coexistence, as for anti-TIF1γ/α  in 
inflammatory myositis associated with cancer (5). Moreover, 
anti-dsDNA and anti-Sm antibodies are classic serological 
markers of SLE, with increased titers of anti-dsDNA 
associated with a more active and severe disease such as 
lupus nephritis (6). Anti-topoisomerase I/Scl-70 and anti-
RNA polymerase I/III antibodies are both associated with 
diffuse scleroderma (dcSSc) with increased mortality rates 
due to interstitial lung disease (ILD) and renal crisis, while 
anti-centromere antibodies (ACA) are commonly detected 
in the limited cutaneous form of SSc (lcSSc), which may be 
related to the onset of pulmonary arterial hypertension (7). 
Myositis-specific antibodies (MSA) include autoAbs 
directed against tRNA synthetases, anti-SRP, anti-Mi-2, and 
anti-TIF-1γ. Among the anti-tRNA synthetases antibodies, 
anti-Jo-1 is the most frequently reported and this class of 
autoAbs is commonly associated with the occurrence of 
arthritis, myositis, ILD, Raynaud’s phenomenon (RP), fever 
and mechanic’s hands (8).
Recently, a novel ANA specificity defined by dense fine 
speckled (DFS) pattern has been reported but it is now 
considered the most frequent ANA pattern in healthy 
individuals, thus it may have a protective role towards the 
development of SARD (9).
As described, the identification of a specific autoAb is 
important to define the diagnosis and the prognosis of 
specific SARDs such as SLE and SSc. However, the diagnosis 
of SARD might be challenging when clinical manifestations 
are weak, heterogeneous and uncommon, and in those 
patients without detectable autoAb, therefore patients do 
not fulfill classification criteria (10-13). The identification of 
rare or non-diagnostic serum autoAbs might be challenging 
as well and in most cases the search for these autoAbs cannot 
be performed routinely but only by research laboratories in 
a few centers worldwide. Furthermore, novel rare autoAbs 
with unknown clinical associations are detected in a small 
number of patients with CTD, and only few observational 
studies have addressed these infrequent serological markers 
and published data that mostly derive from single case 
reports. Therefore, the diagnostic and prognostic value of 
these markers, as well as their potential role in monitoring 
disease activity and predicting specific organ involvement, 
still remains unknown. 
Systematic literature review for the identification 
of rare autoAbs in rheumatic diseases
Based on the principles described above, we conducted 
a systematic literature review to identify the prevalence 
and clinical significance of rare autoAbs in SARD. The 
systematic review procedures we adopted are in line with 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (14). The structured 
literature research was conducted as of January 20th 2017 in 
the following databases: The Cochrane Library, PubMed/
MEDLINE and EMBASE. Search terms included the 
medical subject headings (MeSH) or Emtree terms for 
“systemic sclerosis”, “systemic lupus erythematosus”, 
“sjögren’s syndrome”, “dermatomyositis”, “polymyositis”, 
“mixed connective tissue disease”, “connective tissue 
disease”, “anti-synthetase syndrome”, “autoantibodies”, 
“rare”, “prevalence”, and “clinical significance”. Titles 
and abstracts were screened to determine if they met the 
inclusion criteria and if they were of potential interest, then 
two independent reviewers (Bianca Palermo and Elena 
Generali) selected relevant abstracts. Articles of seminal 
importance were included in the final analysis. 
Inclusion criteria
Observational studies, case reports and clinical trials were 
included.
Exclusion criteria
Articles not concerning SARD, and reviews or editorials 
in languages different from English, if including children 
or animals, were excluded to limit the literature review to 
adults and because no funding was available for translation. 
The selection process was performed by two authors, based 
on titles, abstracts and subsequently full text papers. Figure 1 
represents the flowchart of the selection process of this 
systematic literature review.
Data extraction
The year of publication, study design, number of patients 
and demographic data were recorded. The outcome was 
defined by the identification of rare autoAbs and their 
prevalence and clinical significance in SARD. Articles were 
divided into categories depending on the disease. 
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Results of the systematic literature review
The literature search allowed us to identify articles (n=116) 
that are described in the Tables below, that show the 
prevalence and clinical significance of autoAbs in each 
specific SARD. 
AutoAbs in SLE
SLE i s  a  chron ic  sy s temic  au to immune  d i sea se 
characterized by the positivity of specific autoAbs, namely 
anti-dsDNA and anti-Sm, but several other rare autoAbs 
have been reported in association with SLE as described 
in Table 1. The appearance of the autoAbs in SLE has been 
demonstrated to start years before the clinical onset of the 
disease, thus autoAbs in SLE patients have are fundamental 
for early diagnosis and treatment (2).
Among the rare autoAbs identified in SLE patients, anti-
RNP antibodies are frequently detected in SLE patients 
(15,19,20,22-26,28-30) with a prevalence ranging from 9.5% 
to 30% (15,19,20,22,24,31). They have been reported in 
association with neuropsychiatric SLE (NPSLE), and in case 
reports in association with anti-CASPR2 antibodies (32), 
shrinking lung syndrome (30) and Crohn’s disease (28). 
Anti-Ku antibodies have been detected in the sera of 18 
(11.6%) African American SLE patients, while they were 
not found in SLE Caucasian patient (25,33). Anti-NKG2A 
antibodies have been detected in one patient with SLE, in 
particular in association with vascular involvement and deep 
venous thrombosis, renal involvement, progressive alveolitis 
and increased levels of interferon α (17). Anti-replication 
protein A antibodies (anti-RPA) have been found in 1.4% of 
SLE patients (and in 2.5% of SjS patients), with a subset of 
SLE without other autoAbs commonly found in SLE (27). 
Very high titers of antibodies to glucose-6-phosphate 
isomerase (anti-GPI) were reported in one patient with SLE 
with articular involvement (21). Anti-neuronal antibodies 
are being evaluated in NPSLE, i.e., anti-VGCK, CASPR2, 
NMDA-R, LGI1, GAD, AMA-R, GABAB-R antibodies; 
however, Karaaslan et al. found that, in a cohort of eighteen 
SLE patients with epilepsy, only one female patient had 
anti-GAD, one female patient with hippocampal sclerosis 
on magnetic resonance imaging was CASPR-2 antibody 
positive, whereas four female patients showed hippocampal 
neutrophil staining reflecting antibodies against unknown 
neuronal cell surface antigens (18). One case of anti-VGKC 
positive antibodies in a SLE patient followed by acquired 
neuromyotonia development was reported (29). Another 
autoAb described in SLE patients is represented by anti-
GW182 autoAbs that have been detected in SLE and 
SjS patients, mostly female, and interestingly, six patients 
manifested neurological disease (16).
AutoAbs in SSc
Serological markers of SSc are shown in Table 2. AutoAbs 
to nucleolar antigens (ANoA) have been reported to occur 
in 8–47% of sera from patients with SSc (41,43,52), and 
they include PM-Scl (57), RNA polymerase I (41), Th/To 
(43,57,58), and small nucleolar RNP particles, such as U3 
RNP/fibrillarin (51,52). 
The prevalence of anti-U3 RNP/fibrillarin antibodies 
ranges between 1.1–18% in SSc patients, who are more 
likely to be African American male patients with dcSSc 
and younger age at disease onset (35,36,43,46,47,51-53, 
Figure 1 Flowchart of the articles selection process reporting 
autoAbs in SARD, then described in the present review.
Record identified through 
database searching
(n=3,179)
Record screened
(n=2,790)
Full text articles 
excluded
(n=47)
Articles retrieved by free 
search 
(n=41)
116 articles included
Records after duplicates 
removed 
(n=2,790)
Full text articles 
assessed for eligibility
(n=122)
Records excluded 
(n=2,668)
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Table 1 Prevalence and clinical significance of rare serum autoAbs in systemic lupus erythematosus (SLE)
Study Year Disease
Study 
design
Number of cases/
controls
Autoantibody Methods Main clinical associations
Black (15) 2002 SLE (12.5%) 
and SCLE 
(1.3%)
Case-
control
24/76 Anti-U1RNP Review of 
medical 
records
More prevalent in SLE than SCLE 
patients
Eystathioy 
(16)
2003 SLE, SjS Cohort 200 Anti-GW182 Laser bead 
IF
Eighteen subjects, mostly women 
(17, 94.4%), 4 with SLE and 5 with 
SjS; 6 patients had neurological 
disease
Hagberg 
(17)
2013 SLE Case-
control
SLE [94]; SjS [60]; 
HC [30]
Anti-NKG2A Flow 
cytometry
Vasculitis, skin rashes, renal 
involvement, and progressive 
alveolitis in 1 patient with increased 
levels of IFN-α; anti-Sm and anti-
RNP were also present
Karaaslan 
(18)
2017 NPSLE Case-
control
SLE [18]; HC [50] Anti-neuronal 
antibodies 
(VGKC, CASPR2, 
NMDA-R, LGI1, 
GAD, AMA-R, 
GABAB-R)
ELISA and 
RIA
SLE patients with epilepsy, 
hippocampal neuronal staining 
(4/18)
Lee (19) 2002 SLE Cohort 175 Anti-RNP N/A Lupus enteritis
Lin (20) 2012 Late-onset 
SLE (≥50 
years)
Cohort 158 Anti-U1RNP; 
Anti-RibP
IIF (Hep-
2), Crithidia 
luciliae
Hematological (61.4%), renal 
(57.0%) and articular (53.2%) 
involvement most common, CNS 
affection was rare (3.2%)
Matsumoto 
(21)
2003 SARD Case-
control
578 (RA 291, PsA 20, 
JRA 4, SpA 46, UA, 
80, arthralgia 16, viral 
arthritis 3, SLE 38, 
SjS 20, sarcoidosis 
20, CD 40); 136 HC
Anti-glucose-
6-phosphate 
isomerase (anti-
GPI)
ELISA with 
recombinant 
and native 
GPI, IB
Very high titers were found in 
1 SLE, 1 seronegative RA, and 
1 RA with severe extraarticular 
manifestations
Patsinakidis 
(22)
2016 SLE, SCLE, 
CLE
Cohort 402 (CLE 296, SLE 
with CLE 58, SLE  
w/o CLE 48)
Anti-U1RNP; 
Anti-histone; 
Anti-Jo-1
IIF, ELISA Presence of anti-U1RNP as 
positive predictor for CLE in SLE 
patients (38.6% vs. 16.7% in SLE 
without CLE patients)
Su (23) 2014 SLE with LN Cohort 559 Anti-RNP
Anti-Jo-1
N/A Numbness and functional 
gastrointestinal problems were the 
most common symptoms. Only 
anti-Ro/SSA was independently 
associated with peripheral 
neuropathy in SLE-LN patients
Van Venrooij 
(24)
1990 SLE Cohort 118 Anti-U1snRNA CIE, RNA-IP, 
IB
SLE or SLE overlap syndromes
Wang (25) 2001 SLE Cohort African American 
[155]; Caucasian 
[126]
Anti-Ku; Anti-
nRNP
IP Anti-Ku were detected in sera 
from 18/155 African American 
patients with SLE (12%) vs. 0/126 
Caucasian patients. Anti-nRNP 
(63% vs. 16%) and anti-Sm (23% 
vs. 7%) were also more common in 
African American patients
Table 1 (continued)
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Table 1 (continued)
Study Year Disease
Study 
design
Number of cases/
controls
Autoantibody Methods Main clinical associations
Xi (26) 2016 SjS, SLE, 
RA, UCTD, 
DM
Cohort 180 Anti-MSA; Anti-
RNP
IIF and IB The most frequent clinical 
symptoms in anti-MSA (+) patients 
were arthralgia (35.7%) and sicca 
(28.5%)
Yamasaki 
(27)
2006 SLE, PM/
DM, SjS, 
SSc, RA
Cohort 1,119 (276 SLE, 43 
PM/DM, 47 SSc, 40 
SjS, 35 RA)
Anti-RPA IP, ELISA, IIF, 
WB
Anti-RPA-positive patients may 
form a unique group of SLE 
patients (interstitial lung disease, 
autoimmune thyroiditis/hepatitis C 
virus/pernicious anemia) without 
other autoantibodies commonly 
found in SLE
DM, dermatomyositis; ELISA, enzyme linked immunosorbent assay; IB, immunoblotting; IIF, indirect immunofluorescence; IP, 
immunoprecipitation; LN, lupus nephritis; MSA, mitotic spindle apparatus; N/A, not available; NPSLE, neuropsychiatric lupus; PM/DM, 
polymyositis/dermatomyositis; RA, rheumatoid arthritis; RIA, radioimmunoassay; RPA, replication protein A; SCLE, subacute cutaneous 
lupus erythematosus; SjS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; UCTD, undifferentiated 
connective tissue disease; WB, western blot.
56,59,60). In contrast, Tormey et al.  found a high 
proportion of Caucasian patients with lcSSc and anti-U3 
RNP/fibrillarin positivity (61). In additional reports, 
anti-U3 RNP/fibrillarin antibodies are associated with 
higher prevalence of hypo/hyper- skin pigmentation 
(51,53), calcinosis (51), digital pitting scars and/or ulcers 
(51,53), digital amputation (62), myositis (47,51,60,61), 
PAH (51,53,61), pulmonary fibrosis (35,46,52,61), diarrhea 
and gastric antral vascular ectasia (GAVE) (59,62), cardiac 
and renal involvement (35,59,61). Arnett et al. found a 
significant association between anti-U3 RNP/fibrillarin and 
the HLA class II haplotype DRB1*1302, DQB1*0604; in 
addition, one or more HLA-DQB1 alleles *0604, *0301, 
*0602, and/or *0302 were detected in all anti-U3 RNP/
fibrillarin positive patients who joined the study (35). 
Furthermore, anti-U3 RNP/fibrillarin may be more 
frequently related to the rare occurrence of SSc/ANCA-
associated vasculitis (AAV) than the other scleroderma-
specific antibodies. Glomerulonephritis, renal arteritis, and 
pulmonary fibrosis occur more frequently than expected in 
SSc/AAV overlap (38), and a case of nodular scleroderma 
with positive anti-U3RNP/fibrillarin antibodies has been 
reported (63,64).
Anti-RNA polymerase (RNApol) antibodies are directed 
towards the antigens called RNA polymerase I–III, and anti-
RNApolIII antibodies are the most relevant as they have 
been recently included in the SSc classification criteria (65). 
Their identification has been possible in the past 
thanks to a time and labor consuming technique called 
“immunoprecipitation” until the late 90’s when a specific 
RNAP ELISA was developed and validated as described 
by Chang et al. (33). This allowed the large scale and 
rapid identification of anti-RNApol antibodies in a clinical 
diagnostic laboratory setting to identify SSc patients who 
are at risk for developing SSc with these autoAbs (66,67). 
Anti-RNApol antibodies are found in 1.1% to 15% of 
SSc patients (33,36,37,40,41,45,47,49,52,54,68) and anti-
RNA polymerase I/III positive patients are more likely 
to develop dcSSc with pulmonary involvement, joint and 
tendon involvement, myositis, and a significantly increased 
risk of scleroderma renal crisis (33,37,40,45,47,49,50,52,62). 
However, patients with anti-RNA polymerase III antibodies 
have lower risk of gastrointestinal (GI) manifestations and 
esophageal dysmotility compared to patients with anti-topo 
I/Scl70 (40,62), as well as a lower incidence of pulmonary 
disease (40). A subset of anti-RNA polymerase III positive 
patients may have an atypical clinical presentation with the 
onset of scleroderma prior to Raynaud’s phenomenon (36). 
In 2010, Shah et al. (69) first reported a possible association 
of anti-RNA polymerase I/III with the development of 
malignancy that occurred concomitantly to SSc onset in 
a small number of US patients. Subsequently, the higher 
frequency of synchronous cancer cases in SSc patients with 
anti-RNA polymerase III antibodies has been validated 
in independent SSc patients of European, Australian and 
Japanese populations (34,48,50,54).
Autoantibodies to U1RNP are commonly detected in 
scleroderma overlap syndromes, with frequency ranging 
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Table 2 Prevalence and clinical significance of rare serum autoAbs in systemic sclerosis (SSc)
Study Year Disease
Study 
design
Number of cases/
controls
Autoantibody Methods Main results
Airo’ (34) 2011 SSc Cohort 466 Anti-RNAP III ELISA, IIF, CIE Malignancies more frequent in 
the anti-RNAP III group (7/16) 
than in the anti-topo I (11/101) 
and ACA groups (21/243)
Arnett (35) 1996 SSc Cohort 335 Anti-U3 RNP/
fibrillarin 
IIF, IB, IP More frequent in male African 
American SSc patients with 
cardiac, renal, gut involvement 
and pulmonary fibrosis
Ceribelli 
(36)
2011 SSc/disease 
controls 
(SLE,PM/DM) 
and HC
Case-
control
SSc [119]; SLE 
[434]; PM/DM [85]
Anti-RNAP III IP (K562), 
ELISA 
Rapidly progressive diffuse 
SSc prior to Raynaud’s 
phenomenon in 5/16 (31%) 
anti-RNAP III (+) patients
Chang (33) 1998 dcSSc, lcSSc, 
SLE, MCTD, 
HC
Case-
control
dcSSC [36]; lcSSc 
[53]; SLE [42]; 
MCTD [49]; HC 
[125]
Anti-RNAP I/II/III IP (HeLA), 
ELISA
Diffuse SSc with highly 
prevalent esophageal (62%) 
and pulmonary involvement 
(75%) and myositis (62%)
Codullo (37) 2009 SSc Cohort 46 Anti-RNAP I/III ELISA All developed scleroderma 
renal crisis, and anti-RNAP II 
had dcSSc with pulmonary 
involvement in 3/7 (43%)
Derrett-
Smith (38)
2013 SSc Cohort 2,200 Anti-U3RNP/fibrillarin N/A Overlap SSc/ANCA-
associated vasculitis
Hudson 
(39)
2016 SSc Case-
control 
306 Anti-HMGCR ALBIA, ELISA Significantly lower levels of 
CPK, higher frequency of 
heart involvement, no history 
of statin use
Jaeger (40) 2016 SSc Cohort 695 Anti-RNAP III N/A Lower risk of lung disease 
and gastrointestinal 
manifestations, 4.6 times 
higher incidence of renal crisis 
(95% CI: 1.6–12.4) than anti-
topo I
Kipnis (41) 1990 SSc Cohort 112 Anti-U1RNP, RNAP 
I, U3RNP/fibrillarin, 
PM-Scl, Th/To RNP, 
Ku, NOR90
IP Nine sera had multiple 
specificities
Krzyszczak 
(42)
2011 SSc Cohort 105 (75 
Caucasian, 24 
African-American, 
6 others)
Anti-topo I; Anti-
RNAPIII; Anti-
U3RNP/fibrillarin; 
Anti-Th/To; Anti-PM-
Scl; Anti-U1RNP
IIF, IP Rare coexistence of more 
than one SSc-related 
autoantibody except for anti-
U1RNP and topo I
Kuwana 
(43)
1994 SSc Cohort 275 Japanese Anti-topo I; ACA; 
Anti-U1 RNP; Anti-
RNAP I/II/III; Anti-
U3RNP/fibrillarin; 
Anti-PM-Scl; Anti-Ku
IIF, DID, IP Anti-U1RNP significantly 
higher in Japanese than in 
Caucasian patients
Table 2 (continued)
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Table 2 (continued)
Study Year Disease
Study 
design
Number of cases/
controls
Autoantibody Methods Main results
Lega (44) 2010 PM/DM, 
UCTD, lSSc, 
amyopathic 
DM, 
amyopathic 
DM/SjS/SSc 
overlap
Cohort 9 anti-PM-Scl, 12 
anti-ARS (7 anti-
Jo1, 3 anti-PL7, 1 
anti-EJ, 1 double-
positive for anti-
EJ and anti-OJ), 1 
anti-PM-Scl and 
anti-ARS
Anti-PM-Scl; Anti-
ARS
ELISA, IP Prevalence of respiratory 
symptoms, pulmonary 
function test results and 
HRCT patterns did not 
significantly differ
Maes (45) 2010 SSc, PM/
DM, SLE, SjS, 
RA, MCTD, 
chronic fatigue 
syndrome and 
HC
Prevalence 
case-
control 
242 (70 SSc, 13 
PM, 23 DM, 66 
SLE, 35 SjS, 24 
RA, 11 MCTD). 
36 controls (9 HC, 
27 chronic fatigue 
syndrome)
Anti-PM-Scl 100; 
Anti-RNAPIII
ELISA, IIF, dot 
blot 
At high levels, anti-PM-Scl100 
were exclusively found in SSc 
(4.3%), DM (4.3%) and PM 
(6.1%)
McNearney 
(46)
2007 SSc Cohort 203 (104 Whites, 
39 African 
Americans, 60 
Hispanics)
Anti-U3RNP/
fibrillarin; Anti-RNP
IIF, ID, IP Factors independently 
associated with early 
pulmonary involvement 
included African American 
ethnicity, skin score, serum 
creatinine and CPK levels, 
hypothyroidism and cardiac 
involvement.
Mierau (47) 2011 SSc Cohort 863 (lcSSc 513, 
dcSSc 173, 
scleroderma 
overlap syndrome 
108, UCTD with 
scleroderma 
64, SS sine 
scleroderma 5)
Anti-U1RNP; Anti-
PM-Scl; Anti-M2; 
Anti-RNAP I/II; Anti-
Ku; Anti-U3RNP/
fibrillarin; Anti-Th/To; 
Anti-NOR-90; Anti-
ARS; Anti-p25/p23
IIF, line 
immunoassay, 
IP, ID
Anti-p25/p23 characterise 
a subset within the ACA + 
group strongly associated 
with SSc (71.4%)
Moinzadeh 
(48)
2014 SSc Cohort 2,177 Anti-RNAPIII; Anti-
topo I; Anti-ACA
N/A Patients who developed 
cancer (7.1%; breast (42.2%), 
haematological (12.3%), 
gastrointestinal (11%), and 
gynaecological (11%) had 
higher frequency of anti-
RNAPIII
Motegi (49) 2015 SSc Cohort 246 Anti-RNAP III ELISA High skin score and risk of 
renal crisis
Nikpour 
(50)
2015 SSc Cohort 451 Anti-RNAPIII ELISA Independently associated 
with renal crisis (OR 3.8), 
diffuse disease (OR 6.4), joint 
contractures (OR 2.5) and 
malignancy diagnosed within 
5 years of onset of SSc skin 
disease (OR 4.2)
Table 2 (continued)
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Table 2 (continued)
Study Year Disease
Study 
design
Number of cases/
controls
Autoantibody Methods Main results
Okano (51) 1992 SSc Case-
control
416 cases; 264 
controls
Anti-U3RNP/fibrillarin IIF, IP More frequent in African 
American patients with dcSSc
Okano (31) 1996 SSc, PM/DM, 
SLE, overlap 
syndromes, 
SjS
Cohort 1,171 (SSc 
548, PM/DM 
193, overlap 
syndromes 164, 
SLE 194, SjS 72)
Anti-U5snRNP IP, IIF, IB Identified in a patient with 
SSc/PM overlap syndrome 
and with RP, sclerodactyly, 
puffy fingers, esophageal 
hypomotility and inflammatory 
myopathy
Reimer (52) 1988 SSc Cohort 646 Anti-RNAP I; Anti-
U3RNP/fibrillarin; 
Anti-PM-Scl
IIF, IB, IP Anti-RNAP I were associated 
with dcSSc of short duration, 
joint and tendon involvement, 
higher prevalence of renal 
crisis
Reveille (53) 2001 SSc Cohort GENISOS (54 
Hispanics; 
28 African 
Americans; 79 
White Americans). 
HLA analysis 
(77 Hispanics; 
77 African 
Americans; 192 
White Americans)
Anti-U3RNP/fibrillarin IIF, IP, ID HLA-DQB1*0301 was 
significantly associated with 
SSc in all 3 ethnic groups
Saigusa 
(54)
2015 SSc Cohort 261 Anti-RNAP III ELISA The prevalence of malignancy 
was significantly higher in 
patients with anti-RNAP III 
(7/22, 31.8%) than in those 
with anti-topo I (2/82, 2.4%) 
and ACA (8/137, 5.8%)
Sujau (55) 2015 SSc and HC Case-
control
SSc [31]; HC [11]; 
SLE [6]; RA [5]; 
SjS [A]; IIM [1]; 
MCTD [1]; SpA [2]; 
PsA [1]
Anti-PM-Scl-100/-75; 
Anti-Ku; Anti-Ro-52; 
Anti-RNAP III (RP11 
and RP155); Anti-
fibrillarin (U3RNP); 
Anti-NOR 90 Anti-Th/
To; Anti-PDGFR
Immunoblot Anti-PM-Scl75 was 
associated with overlap 
syndrome, and anti-CENP A 
with vasculitic rash
Yang (56) 2003 SSc Cohort 220 (59 ANoA+, 
161 ANoA−)
Anti-hU3-55K; Anti-
U3RNP/fibrillarin; 
Anti-Mpp10
IIF, IB, IP The 74% (23/31) of the anti-
U3RNP/fibrillarin + sera also 
had anti-Mpp10, but only 
32% (10/31) were positive for 
anti-hU3-55K
ACA, ant i -centromere ant ibodies;  ANoA,  ant inucleolar  autoant ibodies;  ARS,  aminoacyl- tRNA synthetases;  CIE, 
counterimmunoelectrophoresis; DID, double immunodiffusion; ELISA, enzyme-linked immunosorbent assay; dcSSc, diffuse cutaneous 
systemic sclerosis; HC, healthy controls; IB, immunoblotting; IIF indirect immunofluorescence; IIM, idiopathic inflammatory myopathy; IP, 
immunoprecipitation; lcSSc, limited cutaneous systemic sclerosis; MCTD, mixed connective tissue disease; N/A, not available; OR, odds 
ratio; PM/DM, polymyositis/dermatomyositis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RNAP, RNA polymerase; RP, Raynaud’s 
phenomenon; SjS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; SSc, systemic sclerosis; UCTD, 
undifferentiated connective tissue disease.
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from 4.8% to 10.7% in SSc patients (41,47). Specific 
autoantibodies to U5snRNP represent a rare finding (2.4%) 
in patients with SSc-PM overlap syndrome (31). Anti-Ku 
and anti-PM-Scl antibodies, when found in SSc patients 
(about 1.2–1.8% and 4.0–4.9%, respectively), are often 
related to overlap syndromes with muscular manifestations, 
including creatine phosphokinase (CPK) elevation (45). 
Antibodies to p25/p23 characterize a subset within the 
ACA-positive SSc patients, which is strongly associated with 
SjS symptoms (47). A case report of nephrotic syndrome in 
a patient with lcSSc and anti-ribosomal P antibodies was 
found (70). The association of anti-HMGCR antibodies 
and necrotizing autoimmune myositis (NAM) is well-
known (71,72). Such autoAbs have been identified in 1.3% 
of SSc patients; these subjects show significantly lower 
levels of CPK, a higher frequency of heart involvement and 
pulmonary hypertension, and no history of statin use (39). 
A DFS pattern at IIF and anti-DSF70 antibodies have 
been reported to be less frequent in SSc patients than 
healthy controls (73-76).
AutoAbs in polymyositis/dermatomyositis (PM/DM) and 
in the anti-synthetase syndrome
As described in the results shown in Table 3, anti-synthetase 
antibodies identified in myositis patients have a variable 
prevalence, and this depends on each single specificity. In 
particular, anti-Jo-1 antibodies have the highest prevalence 
ranging from 0.5% to 54.7% (82,88), while other anti-
synthetase antibodies have lower prevalence, as for anti-
PL-7 0.5–9.3% (82,90), anti-PL-12 1.5–19.2% (82,88), 
anti-OJ 0.5% (82,88), anti-EJ 1–3% (82,88). Antibodies to 
asparaginyl-tRNA synthetase (anti-KS) occur in 0.3–0.5% 
of patients with CTD—especially in Japanese patients 
(62.5%)—most of them presenting ILD (88%)—while an 
association with myositis was rarely found, as it was detected 
in 0% of Japanese subjects with PM/DM and in 25% of all 
positive patients. Interestingly, cancer history was reported 
in 25% of anti-KS positive patients (83), thus it may be very 
important to be able to identify this rare autoAb not only for 
diagnostic but also for prognostic evaluations. With regard 
to clinical manifestations, overall anti-synthetase antibodies 
are more frequent in female patients with diffuse cutaneous 
involvement similarly to limited SSc, arthralgia, joint 
deformities, high CK levels (88), and overlap myositis (90). 
Lung involvement is a common manifestation of anti-
synthetase syndrome, and anti-Jo-1 antibodies have been 
reported in association with ILD (91,92), even though a 
larger study reported that anti-Jo-1 (+) patients have higher 
rates of myositis and arthralgia than ILD, as well as higher 
CK levels compared to anti-PL-12 and PL-7 (+) patients (81). 
Anti-synthetase antibodies have also been detected in a 
case of cryptogenic organizing pneumonia (93) and in 
association with uncommon clinical manifestations such as 
aphthous-like ulcerations and xerostomia (94). As for their 
prognostic significance, anti-PL-12 and PL-7 antibodies 
are related to lower survival rates (81,82), and anti-EJ 
antibodies have been reported in a case of fatal myocarditis 
in anti-synthetase syndrome (95). 
Rare autoAbs reported in PM/DM patients include anti-
Mi-2 (5%) 90), anti-SRP (2.8%) (90), anti-Ku (1–1.7%) 
(90,96) and anti-HMGCR (3%) (96,97). In particular, anti-
Mi-2 and anti-SRP antibodies are more common in female 
patients affected by DM, while DM skin manifestations 
are less frequently seen in anti-Ku and anti-SRP positive 
patients. Anti-SRP antibodies have been associated with 
higher CK levels (90) in clinically relevant myositis (86), and 
more severe clinical symptoms, such as rapidly developing 
muscle weakness and atrophy, dysphagia, ILD complicated 
by massive pleural effusion and respiratory insufficiency 
(89,98-100) with poor response to immunosuppressive 
treatments (101). 
Anti-HMGCR antibodies have been reported in 
several studies (77,78,102-106), in particular in association 
with necrotizing autoimmune myositis (NAM) (44.9%), 
followed by PM (4.4%) and DM (1.9%) (107). The titer 
of anti-HMGCR antibodies seems to correlate with CPK 
levels (106) and their association with statin therapy is 
controversial since some studies report that less than 50% 
of patient have used statins (77,80,97,105), while other 
reports suggest a strong association in a higher percentage 
of cases (89,104,107,108). A case of NAM associated 
with anti-HMGCR antibodies with severe head and neck 
involvement, resembling a retropharyngeal abscess, has also 
been reported (71). 
As for anti-TIF1γ antibodies, they have been detected 
mainly in cases of paraneoplastic myositis associated in 
particular with solid tumors such as breast cancer (109), 
thus they have not only a diagnostic but also a prognostic 
value for myositis patients. 
When histology is considered, anti-Mi-2 and anti-
synthetase antibodies are more frequent in cases with 
typical DM involvement, while unspecified myositis is the 
most frequent pathologic finding in patients with anti-
Ku antibodies, and NAM is present in 75% of anti-SRP 
positive subjects (90). 
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Table 3 Prevalence and clinical significance of rare serum autoAbs in polymyositis/dermatomyositis (PM/DM) and anti-synthetase syndrome
Study Year Disease
Study 
design
Number of cases/
controls
Autoantibody Methods Main results
Allenbach 
(77)
2014 Necrotizing 
myopathy
Cohort 206 Anti-HMGCR ALBIA Statin exposure was present in 
44.4% [20] of patients
Alvarado-
Cardenas 
(78)
2016 Statin-
associated 
autoimmune 
myopathy
Cohort 23/135 Anti-HMGCR ELISA 23 cases, 14 (82%) were 
exposed to statins, 15 (88%) had 
IMNM at muscle biopsy
Coppo (79) 2002 Myositis Cohort 5 Anti-U1snRNP ELISA, CIE, 
dot blot, DID
Muscle weakness is present 
since the onset, with pulmonary 
manifestations, neurological 
symptoms, and symmetric 
arthritis involving distal joints
Drouot (80) 2014 Necrotizing 
myopathy
Case-
control
150 NAM; 142 
SARD; 100 HC
Anti-HMGCR IP, ALBIA, 
WB
Positive in 24% (37 cases), with 
higher CPK levels and only 40% 
exposed to statins
Hervier (81) 2012 Anti-
synthetase 
syndrome
Cohort 233 Anti-synthetase 
antibodies (anti-
Jo-1, anti-PL-7, 
anti-PL-12)
N/A Anti-PL7 and PL12 are very 
similar and clearly distinct from 
anti-Jo1 patients for reduced 
survival (P=0.012) and had 
higher frequency of ILD (98%)
Hervier (82) 2013 Anti-
synthetase 
syndrome
Cohort 203 Anti-synthetase 
antibodies (anti-
Jo1, anti-PL-7, 
anti-PL-12
Immunodot Anti-PL7 and PL12 were 
associated at multivariate 
analysis to increased risk of 
death (OR 6.3, 95% CI: 1.1–35.4, 
P=0.038). 
Hirakata 
(83)
2007 CTD (including 
myositis and 
ILD)
Case- 
control
2,500 Anti Asparaginyl-
tRNA synthetase 
(anti-KS)
IP Identified in the sera of 8 patients 
(5 Japanese, 1 American, 1 
German and 1 Korean). Two 
patients had DM, but 7/8 (88%) 
had ILD, 4 arthritis, 1 RP. 2 
patients had history of cancer 
(ovarian and prostate). 7/8 were 
women; all patients were middle-
aged or elderly. Anti-KS were 
found in 3% of patients with 
idiopathic ILD
Lega (44) 2010 PM/DM, 
UCTD, lcSSc, 
amyopathic 
DM, overlap 
syndrome 
amyopathic 
DM/SSc/SjS
Cohort 9 anti-PM-Scl, 12 
anti-ARS (7 anti-Jo1, 
3 anti-PL7, 1 anti-EJ, 
1 double-positive for 
anti-EJ and anti-OJ), 
1 anti-PM-Scl and 
anti-ARS
Anti-PM-Scl; 
Anti-ARS
ELISA, 
immunodot, 
IP 
Extrapulmonary manifestations 
of CTD in all patients, except 1 
with anti-PM-Scl
Nakashima 
(84)
2010 SARD Case-
control
192/21 Anti-CADM-140/
MDA5
IP 11/13 patients positive for 
anti-CADM-140/MDA5 were 
diagnosed with CADM. Anti-
CADM-140/MDA5 antibodies are 
strongly associated with rapidly 
progressive ILD
Table 3 (continued)
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Table 3 (continued)
Study Year Disease
Study 
design
Number of cases/
controls
Autoantibody Methods Main results
Neri (85) 2014 PM/DM, 
cancer-
associated 
myopathy 
(CAM)
Cohort 162 (PM 80, 55 DM, 
CAM 27)
Anti-Jo-1; Anti-
RNP
IIF, CIE CAM were observed in 27 
patients (17%). Breast and 
ovarian cancers were the more 
common (8 and 6 patients). 
CAM were strongly associated 
with DM (24.6% vs. 10.1 % in 
PM), older age and dysphagia at 
disease onset (37% vs. 18.5% in 
IIM)
Pinal-
Fernandez 
(86)
2016 IMNM Cohort 666 Anti-SRP; Anti-
HMGCR
ELISA, IP Anti-SRP positive patients were 
younger and more commonly 
under immunosuppressive 
therapy than anti-HMGCR (38.4 
vs. 53.3 years old, P<0.001; 68% 
vs. 40%, P=0.03)
Pluk (87) 2013 Sporadic 
inclusion body 
myositis, PM/
DM and HC
Case-
control
94 sIBM, 24 DM, 22 
PM, 94 NDM, 32 HC
Anti-Mup44 IB, cDNA 
cloning and 
expression 
of Mup44, IP, 
microarray-
based 
epitope 
mapping
The Mr 44,000 polypeptide 
(Mup44) was identified as 
cytosolic 50-nucleotidase 
1A (cN1A). Anti-Mup44 was 
detected in 60% of the sIBM 
sera at high titer. The 3 major 
autoepitope regions of cN1A 
suggest that relatively small 
fragments of this protein can 
be used to detect anti-Mup44 
in patient sera. One of these 
regions (aa221–243) were 
recognized by all of the anti-
Mup44 positive sIBM sera, but 
not by the sera from HC
Watanabe 
(88)
2011 Anti-
synthetase 
syndrome
Cohort 198 Anti-Jo-1; Anti-
PL7; Anti-PL12; 
Anti-OJ; Anti-EJ; 
Anti-KS
RNA IP Anti-EJ antibodies were positive 
in 3%, anti-PL12 in 1.5%, and 
anti-Jo-1, KS, OJ, and PL7 in 
0.5%
Watanabe 
(89)
2016 IMNM Cohort 460 Anti-SRP; Anti-
HMGCR
ELISA, RNA 
IP
Anti-SRP antibodies are 
associated with more severe 
muscle involvement compared 
to anti-HMGCR (63% vs. 
24%, P<0.001), who had more 
frequently statin exposure (18% 
vs. 4%, P=0.019)
ARS, aminoacyl-tRNA synthetases; ALBIA, addressable laser bead immunoassay; CAM, cancer-associated idiopathic inflammatory 
myopathy; CIE, counterimmunoelectrophoresis, CTD, connective tissue disease; DID, double immunodiffusion; DM, dermatomyositis; 
ELISA, enzyme linked immunosorbent assay; dcSSc, diffuse cutaneous systemic sclerosis; HC, healthy controls; HMGCR, 3-hydroxy-3-
methylglutaryl-coenzyme A reductase; IB, immunoblotting; IIF, indirect immunofluorescence; ILD, interstitial lung disease; IMNM, immune-
mediated necrotizing myopathy; IP, immunoprecipitation; lcSSc, limited cutaneous systemic sclerosis; N/A, not available; PM/DM, 
polymyositis/dermatomyositis; SARD, systemic autoimmune rheumatic diseases; SRP, signal recognition particle; SSc, systemic sclerosis; 
UCTD, undifferentiated connective tissue disease; WB, western blot. 
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A distinct subset of DM, called clinically amyopathic DM 
(CADM), has been associated with anti-CADM-140/MDA5 
antibodies which are strongly related to rapidly progressive 
ILD (84) and in cases of anti-CADM-140/MDA5 positive 
patients with idiopathic pulmonary fibrosis (110). 
AutoAbs in MCTD, Sjögren’s syndrome (SjS) and other 
rheumatic diseases
MCTD is characterized by the overlap of SSc, SLE and RA 
diagnosis in the presence of autoAbs such as anti-synthetase 
antibodies, described in previous sections of this review. 
Other undefined autoAbs directed towards tRNA were 
identified in about 1.9% of sera from patients with SARD, 
and nearly all the positive sera belonged to patients affected 
by either SLE or SjS. Subjects with both anti-tRNA 
synthetase antibodies and anti-RoSSA/LaSSB (57.1%) 
develop annular or papulosquamous recurrent erythema 
in 37.5% of cases (111). Antibodies to NOR 90 were first 
described in a patient with SSc by Rodriguez-Sanchez 
et al., who identified a novel 90-kDa protein recognized 
by autoantibodies that selectively stained the nucleolus-
organizing region (NOR) of chromosomes 13, 14, 15, 21, 
and 22 (112). The 90-kDa autoantigen was later shown to 
be identical to human upstream-binding factor (hUBF), an 
RNA polymerase I-specific transcription factor which plays 
a central role in transcriptional regulation of rRNA (113). 
In search for the NOR 90 specificity among 254 patients 
with various autoimmune rheumatic diseases, Rodriguez-
Sanchez et al. concluded that anti-NOR 90 antibodies were 
associated with SSc. By contrast, Kipnis et al. did not detect 
anti-NOR 90 in sera from 112 patients with SSc (41), while 
Imai et al. (114) and Dick et al. (115) reported the presence 
of antibodies to NOR 90 in patients with heterogeneous 
conditions, including SSc, SLE, RA, SjS, UCTD and other 
non-rheumatic diseases.. 
Among patients with SjS, the occurrence of several rare 
autoAbs and uncommon clinical presentations (such as 
severe motor-dominant weakness in the lower extremities, 
depression, cerebellar ataxia) have been described, for 
example in a patient with anti-neuronal antibodies (116) 
and in a patient with antibodies to Ma2/Ta with progressive 
spastic paresis without evidence of cancer over a 4-year 
follow-up (117). One case of anti-aquaporin 4 antibodies 
positivity had tetraparesis due to recurrent central nervous 
system demyelination, together with distal renal tubular 
acidosis, hypokalemia, medullary nephrocalcinosis, 
respiratory failure, and secondary anti-phospholipid 
syndrome (118). Vandergheynst et al. report the occurrence 
of anti-PM-Scl antibodies in one patient with SjS and ILD, 
without features of SSc or myositis (99).
AutoAbs against the mitotic apparatus (MA) represent a 
subtype of ANA rarely detected in sera from patients with 
SARD. Different MA antigens have been identified so far: 
mitotic spindle apparatus (MSA), centrosome (CE), midbody 
(MB/MSA-2), and centromere-F (CENP-F) (119). After 
the description of anti-MSA antibodies by McCarty et al. 
in 1981 (120), two major classes were identified: autoAbs 
against the nuclear mitotic apparatus protein (NuMA) and 
the kinesin-like protein HsEg5 (121,122). Their prevalence 
is estimated to be less than 1%, with anti-HsEg5 being 
less frequently detected than anti-NuMA (123,124). Anti-
mitotic spindle apparatus antibodies appear to be primarily 
associated with SjS, SLE and UCTD (26,121-124), and the 
most frequent clinical symptoms are arthralgia and sicca 
syndrome (26). 
Discussion
SARD are characterized by the presence of serum autoAbs 
directed against cellular components belonging to 
different tissues and organs, and in this view the first step 
to recognize the presence of an autoimmune response in 
a specific clinical setting is the identification of autoAbs. 
However, autoAbs and serum ANA are not disease specific 
for rheumatic diseases and they can be present also in a 
significant proportion of healthy people (3), as well as in 
other autoimmune conditions, i.e., autoimmune thyroid 
disease (125). AutoAbs specific for SARD have been 
identified and described since the 1990s, and albeit the 
most known (i.e., anti-dsDNA and anti-RoSSA/LaSSB), 
which are also included in the disease classification criteria 
(126,127) and easily tested in routine assays (128), many 
others are rare and they are not available for the routine 
testing. In this view, rheumatologists treating SARD should 
know also the prevalence and clinical associations of rare 
autoAbs, especially for particular rheumatic disease subsets 
and their possible association with malignancy (129). The 
results of the present systematic literature summarize the 
main features of rare serum autoAbs identified in SARD, as 
described in Tables 1-4, and a few novel findings have been 
identified. For example, the number of autoAbs targeting 
the nervous system, as well as the field of neuroimmunology, 
have enormously increased (131). In the present work, 
we have retrieved several articles regarding anti-neuronal 
antibodies in NPSLE (17,18,29,32), however, most of them 
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Table 4 Prevalence and clinical significance of rare serum autoAbs in mixed connective tissue disease (MCTD), Sjögren’s syndrome (SjS) and 
other connective tissue diseases (CTDs)
Study Year Disease
Study 
design
Number 
of cases/
controls
Autoantibody Methods Main results
Andrade 
(121)
1996 SjS Cohort 37 Anti-NuMA1; 
Anti-NuMA2
IIF, IB, IP Anti-NuMA1 react with a 210-kd protein 
previously described as NuMA antigen. 
17 patients with anti-NuMA1 (53%) had 
clinical and lip biopsy findings that met 
the criteria for SjS
Bonaci-
Nikolic (123)
2006 SjS
UCTD
Cohort 6,270 Anti-NuMA1; 
Anti-NuMA2 
(HsEg5); 
Anti-CENP F; 
Anti-CENP F/
centrosome
IIF, ELISA Anti-NuMA1 antibodies were found in 23 
(41%) and -NuMA2 in 7 patients. Most 
of the positive patients had CTD (22/43, 
51.1%), UCTD (7/22) and SjS (6/22) being 
the most common. Anti-NuMA1 positivity 
was associated with SjS, while patients 
with -NuMA2 had various diseases  
(1 SSc, 2 AIH, 1 infection, 1 vasculitis)
Fujii (130) 1996 SjS, 
SSc, 
SLE, RA, 
UCTD
Cohort 91 (SjS 13, 
SLE 21, SSc 
21, RA 14, 
UCTD 10)
Anti-NOR 90 IIF, IB Anti-NOR 90 antibodies were present in 
7 (77.7%) patients with SjS, RA [4] and 
SSc [3], no patient with SLE or UCTD
Mozo (124) 2008 SjS, 
UCTD, 
SLE
Cohort 47 Anti-NuMA; 
Anti-HsEg5
IIF, IB, ELISA, 
chemiluminescence, 
radioimmunoassay
NuMA positivity was mainly associated 
with SjS/sicca syndrome and UCTD. 
Anti-HsEg5 antibodies were detected in 
7 patients, not associated with a specific 
SARD
Owada 
(116)
2002 SjS Case 
report
1 Anti-neuronal 
antibodies
Immunohistochemistry, 
WB
Severe motor-dominant weakness in 
the lower extremities, depressive state, 
cerebellar ataxia, bladder disturbance 
were present in this patient
Piccolo 
(117)
2011 SjS Case 
report
1 Anti-Ma2/Ta Line blot assays Co-occurrence of anti-Ma2 antibodies 
and SjS in a patient presenting with 
a progressive spastic paresis mainly 
involving lower limbs and no tumour over 
a 4-year follow-up
Rajagopala 
(118)
2015 SjS Case 
report
1 Anti-
aquaporin-4 
antibodies
ELISA SjS with distal renal tubular 
acidosis, hypokaliemia, medullary 
nephrocalcinosis, recurrent central 
nervous system demyelination with 
tetraparesis, respiratory failure, 
secondary anti-phospholipids with 
intravenous catheter thrombosis
Whitehead 
(122)
1996 SLE, SjS Cohort 51 MSA-
positive sera 
(43 NuMA,  
7 HsEg5);  
52 SLE sera
Anti-NuMA2 
(HsEg5)
IIF, IB, IP Five of the 7 HsEg5-positive sera had 
SLE, 1 had possible SLE, and 2 had 
SjS. The anti-HsEg5 activity did not 
decrease in titer over time, and there was 
no apparent association with disease 
activity
CTD, connective tissue disease; ELISA, enzyme linked immunosorbent assay; IB, immunoblotting; IIF, indirect immunofluorescence; IP, 
immunoprecipitation; MSA, myositis specific antibodies; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SjS, Sjögren’s 
syndrome; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease.
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are case reports or small case series, thus estimating the 
prevalence of these autoAbs remains difficult. Lastly, we 
confirm that an autoAb called “anti-DFS70” which stands 
for diffuse speckled pattern at IIF has been associated 
negatively with SARD, as it is more frequent in healthy 
subjects (73-76,132-135) and it is rare in SLE patients (132), 
thus maybe representing a protective pattern. 
We must acknowledge that a large variability is 
found when searching for rare autoAbs in SARD, and 
additional unsolved problems are represented by the lack 
of validation, the small number of cases described with 
different prevalence in different ethnic groups and the use 
of different laboratory methods for autoAb identification. 
Further research is needed to strengthen evidence for the 
role of such autoAbs in the clinical assessment of specific 
diseases.
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